Paolo Bonanni is a Full Professor of Hygiene in the Faculty of Medicine and the Director of the Specialization School for MDs in Hygiene and Preventive Medicine at the University of Florence, Italy. Professor Bonanni graduated in Medicine and Surgery (MD) in 1985 and was awarded two specialisations in Hygiene and Preventive Medicine at the University of Genoa, Italy. From 1992 to 2000, he was Associate Professor, before becoming a Full Professor in 2000. Professor Bonanni’s scientific activity has covered the epidemiology and prevention of infectious diseases, particularly viral hepatitis, diphtheria, tetanus, pertussis, influenza, measles, rubella, varicella, and, most recently, bacterial invasive diseases and human papillomavirus, including clinical trials and economic valuation of vaccination strategies. He is the author or co-author of more than 300 scientific publications in international and national journals. Professor Bonanni has been a member of the National Vaccination Commission of the Italian Ministry of Health, and an expert consultant for the European Centre for Disease Prevention and Control (ECDC) based in Stockholm, Sweden. Between 2012 and 2017 he has been a member of the European Technical Group of Experts on Immunization (ETAGE) at WHO Europe, Copenhagen, Denmark. He is standing adviser of the Viral Hepatitis Prevention Board (VHPB), an international independent committee of experts in viral hepatitis prevention, and of the International Human Papilloma Virus Prevention Board an international independent committee of experts on HPV prevention. He received several grants from the Italian Ministry of University and the Italian Ministry of Health (Centre for Disease Control or CCM) on projects regarding vaccine-preventable infections. Paolo Bonanni was research unit leader in 4 EU-funded projects on vaccination, and presently coordinating the University of Florence Unit participating as one of the main partners in the EU Innovative Medicine Initiative on brand-specific influenza vaccination effectiveness named DRIVE (Development of Robust Influenza Vaccine Effectiveness).